ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Files An 8-K Other Events
On January 16, 2019, Adamis Pharmaceuticals Corporation (the Company) issued a press release announcing that its marketing and commercial partner,Sandoz Inc., aNovartisdivision, has launched the Companys SYMJEPI (epinephrine) 0.3 mg Injection product in the United States market for the emergency treatment of allergic reactions (Type 1), including anaphylaxis.
The Companys press release is filed as exhibit 99.1 to this Report.
Financial Statements and Exhibits
Press release dated January 16, 2019.
Adamis Pharmaceuticals Corp Exhibit
EX-99.1 2 ex99-1.htm PRESS RELEASE ADAMIS PHARMACEUTICALS CORPORATION 8-K Exhibit 99.1 Adamis’ Commercial Partner Launches SYMJEPITM (epinephrine) in the US San Diego,…
To view the full exhibit click
About ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP)
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.